Novartis is further bolstering its preclinical pipeline and continuing its hunt for a Xolair successor, nailing down a ...

Japan’s Kyorin Pharmaceutical has entered into a global license agreement with Swiss pharma giant Novartis relating to ...

M223, a preclinical drug for inflammatory diseases, with potential milestone payments of $777.5M plus royalties.

IN8bio has unveiled a new T cell engager (TCE) platform, marking its first major push into autoimmune disease. The biotech, which previously focused on oncology, introduced INB-619, a CD19-targeted ...

Novartis: 1996 – 2013 Dr Daniel Vasella was the first CEO of the newly merged company. Vasella was hired by Sandoz back in 1988 and remained there until 1992 when he was promoted to CEO of its ...

Novartis’ Zolgensma gene therapy for spinal muscular atrophy is the most expensive drug in the world, but that hasn’t stopped it making a strong start in the US market. Zolgensma (onasemnogene ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Novartis works with the patient community around the world to discover new ways to improve and extend people’s lives. Our significant investment in research and development underpins our commitment to ...

After hours: February 28 at 4:09:16 PM EST Loading Chart for MNOV ...

After hours: February 28 at 7:55:42 p.m. EST ...